Encompass Health Research and Development Expenses 2010-2025 | EHC

Encompass Health annual/quarterly research and development expenses history and growth rate from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Encompass Health research and development expenses for the quarter ending March 31, 2025 were $0M, a 0% increase year-over-year.
  • Encompass Health research and development expenses for the twelve months ending March 31, 2025 were $0M, a 0% increase year-over-year.
  • Encompass Health annual research and development expenses for 2024 were $0B, a 0% decline from 2023.
  • Encompass Health annual research and development expenses for 2023 were $0B, a 0% decline from 2022.
  • Encompass Health annual research and development expenses for 2022 were $0B, a 0% decline from 2021.
Encompass Health Annual Research and Development Expenses
(Millions of US $)
2024 $0
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Encompass Health Quarterly Research and Development Expenses
(Millions of US $)
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $11.734B $5.373B
Encompass Health Corporation is a provider of integrated healthcare services. It offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. The company delivers high-quality, cost-effective, integrated care in the healthcare space. It provides a continuum of facility-based and home-based post-acute services for its patients and their families, which will gain more prevalence as coordinated care and integrated delivery payment models, such as accountable care organizations and bundled payment arrangements. The company operates through two segments: Inpatient Rehabilitation as well as Home Health and Hospice business.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $19.755B 19.47
DaVita (DVA) United States $11.050B 14.67
Chemed (CHE) United States $8.342B 26.22
Elanco Animal Health (ELAN) United States $5.940B 12.72
Option Care Health (OPCH) United States $5.214B 23.24
RadNet (RDNT) United States $4.181B 88.48
Amedisys (AMED) United States $3.128B 21.04
LifeStance Health (LFST) United States $2.228B 0.00
Addus HomeCare (ADUS) United States $2.041B 22.41
Astrana Health (ASTH) United States $1.666B 41.26
U.S Physical Therapy (USPH) United States $1.125B 29.05
Aveanna Healthcare Holdings (AVAH) United States $1.054B 60.00
Pennant (PNTG) United States $0.985B 36.18
Atai Life Sciences (ATAI) Germany $0.278B 0.00
Daxor (DXR) United States $0.037B 0.00
Ontrak (OTRK) United States $0.007B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.005B 0.00
Psychemedics (PMD) United States $0.000B 0.00